Table 2 Clinical measures and outcomes according to patient group.
MASLD N = 88 | Viral hepatitis N = 113 | Alcoholic liver disease N = 63 | Alcoholic liver disease and Viral hepatitis N = 62 | p-value | |
|---|---|---|---|---|---|
Follow-up duration (months), median (IQR) | 53 (28.3–77.3) | 59 (33.5–80) | 56 (23–79) | 47 (26–74) | 0.33 |
Deceased, No. (%) | 49 (55.7) | 49 (43.4) | 30 (47.6) | 24 (38.7) | 0.17 |
Death age, mean ± SD | 70 ± 11.7 | 64.6 ± 11.7 | 63.5 ± 10.6 | 57.3 ± 11.6 | < 0.001 |
Months after varices diagnosis, median (IQR) | 25 (9–45) | 15 (1–38) | 14.5 (3.8–29.3) | 16.5 (5.3–25.8) | 0.27 |
First year after varices diagnosis, No. (%) | 14 (28.6) | 23 (46.9) | 14 (46.7) | 9 (37.5) | 0.23 |
Months after varices bleeding, median (IQR) | 20 (1–38) | 0.5 (0–22) | 4 (0.5–19.5) | 5 (0.8–21.8) | 0.15 |
First year after varices bleeding, No. (%) | 11 (47.8) | 12 (66.7) | 9 (69.2) | 7 (70) | 0.45 |
Transplanted, No. (%) | 2 (2.3) | 5 (4.4) | 0 (0) | 0 (0) | 1 MASLD vs. other |
Hepatocellular carcinoma, No. (%) | 3 (3.4) | 6 (5.3) | 1 (1.6) | 1 (1.6) | 1 MASLD vs. other |
MELD-Na score* | 22 (16–26.5) | 21 (14.8–31.3) | 29 (25.5–38.5) | 30.5 (18.5–39.8) | 0.01 |
22 (16–26.5) | 26 (17–36) | 0.02 MASLD vs. other |
